Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
24/01/2018
Vaccibody AS announces conditional approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)) as well as approval by the central ethics committee in Heidelberg (Ethikkommission Medizinische Fakultät Heidelberg); Reiterates estimate to start cancer neoantigen trial in Q1, 2018.
08/01/2018
Vaccibody AS announces pre-clinical data showing improved ability to elicit strong killer T cell responses to neoantigens thus supporting the promise of their DNA vaccine platform for anti-cancer therapy; Attending JP Morgan in San Francisco.
12/12/2017
Vaccibody AS announces finalization of the recruitment in the phase IIa part of its study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix; appointment of Agnete B. Fredriksen as President & CSO and Mette Husbyn as Chief Technical Officer (CTO).
09/11/2017
QUARTERLY REPORT – 2017 Q3
31/08/2017
QUARTERLY REPORT – 2017 Q2
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer